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Abstract
The majority of currently marketed drugs contain a mixture of enantiomers; however, recent evidence suggests that individual enantiomers can have
pharmacological properties that differ importantly from enantiomer mixtures. Escitalopram, the S-enantiomer of citalopram, displays markedly different
pharmacological activity to the R-enantiomer. This review aims to evaluate whether these differences confer any significant clinical advantage for
escitalopram over either citalopram or other frequently used antidepressants. Searches were conducted using PubMed and EMBASE (up to January 2009).
Abstracts of the retrieved studies were reviewed independently by both authors for inclusion. Only those studies relating to depression or major
depressive disorder were included. The search identified over 250 citations, of which 21 studies and 18 pooled or meta-analyses studies were deemed
suitable for inclusion. These studies reveal that escitalopram has some efficacy advantage over citalopram and paroxetine, but no consistent advantage
over other selective serotonin reuptake inhibitors. Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake
inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents. This review suggests that the mechanistic
advantages of escitalopram over citalopram translate into clinical efficacy advantages. Escitalopram may have a favourable benefit-risk ratio compared
with citalopram and possibly with several other antidepressant agents.
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Introduction
The selective serotonin reuptake inhibitor (SSRI) class of anti-
depressants has had a substantial impact on the treatment of
depression since its introduction in the mid-1980s. Escitalopram
is an SSRI that is the most selective serotonin-speciﬁc antide-
pressant marketed to date (Lam and Annemans, 2007).
Escitalopram is the S-enantiomer of the racemate citalopram.
The eﬃcacy of citalopram as an antidepressant is almost
entirely due to the activity of escitalopram; the S-enantiomer
is approximately 150 times more potent as a reuptake inhibitor
than R-citalopram in vitro (Hyttel et al., 1992). The mode of
action of escitalopram also diﬀers from R-citalopram in that it
displays a unique interaction with the human serotonin reup-
take transporter (SERT) and there is evidence to suggest that it
has a self-potentiating eﬀect on the SERT, which is mediated by
an allosteric binding site that is distinct from the primary, high-
aﬃnity binding site on the SERT (Plenge et al., 2007).
There is a growing trend to develop drugs that comprise a
singleenantiomer,asopposedtoamixtureofenantiomers.This
trend has largely been prompted by the need to develop drugs
withimprovedtolerabilityproﬁles,anditissupportedbyrecom-
mendations issued by the Food and Drug Administration
(FDA) and the European Medicines Agency for the develop-
ment of chiral drugs (Food and Drug Administration, 1992;
Committee for Proprietary Medical Products, 1993). Although
theracemicnatureofdrugshasbeen recognized formanyyears,
it was frequently assumed that only one enantiomer was
pharmacologically active; the other enantiomer was considered
inactive, or was assumed merely to contribute to the side-eﬀect
proﬁle of the drug (Ariens et al., 1983; Waldeck, 2003).
However, extensive research has shown that two enantiomers
can behave synergistically or antagonistically. Consequently,
drugs that are racemates should be considered to be a mixture
of potentially diﬀerent drugs, with potentially diﬀerent
therapeutic and adverse properties (Cordato et al., 2003;
McConathy and Owens, 2003); for example, the b-blocker labe-
talol comprises four diﬀerent stereoisomer combinations, which
canhavemarkedlydiﬀerentphysiologicaleﬀects(Brittainet al.,
1982). Single enantiomer drugs, such as escitalopram, can,
therefore, potentially oﬀer a number of distinct beneﬁts, specif-
ically with respect to inter-patient pharmacokinetic and phar-
macodynamic variability, as well as reducing toxicity arising
from the presence of the therapeutically redundant enantiomers
(Leonard, 2001) and improving therapeutic eﬃcacy.
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Email: david.taylor@slam.nhs.ukIn Europe, escitalopram is currently approved for use in
major depressive disorder (MDD), panic disorder, social anx-
iety disorder, generalized anxiety disorder and obsessive com-
pulsive disorder (Baldwin et al., 2007). Prior to approval of
escitalopram in 2002 for the treatment of MDD in the USA,
the FDA conducted an extensive review of its clinical eﬃcacy
and tolerability data and concluded that escitalopram did not
have notable eﬃcacy or tolerability advantages over other mar-
keted antidepressants (Food and Drug Administration, 2002).
However, there have been many studies conducted since that
time. This qualitative review of the literature sought to examine
the more recent clinical literature and assess whether there is
evidence of a clinical advantage for escitalopram over either
citalopram or other frequently used antidepressants.
Methods
Searches were conducted using PubMed and EMBASE. With
PubMed, several independent searches were performed.
The keyword ‘escitalopram’ was used in combination with ‘pla-
cebo’, ‘citalopram’, ‘sertraline’, ‘paroxetine’, ‘ﬂuoxetine’, ‘dulox-
etine’ and ‘venlafaxine’ in separate searches. All searches were
limited to trials in adults, clinical trial and English language.
Searches were limited to the title/abstract ﬁelds. The four
searches were then cross-referenced to avoid duplication. For
the EMBASE search, the keyword ‘escitalopram’ was used
alone and the search limited to English language and clinical
trials. All retrieved titles were then cross-referenced with the
searches from PubMed to avoid duplication. No date limits
w e r ea p p l i e dt oa n yo ft h es e a r c h e s; however, the searches were
completed in January 2009 and do not, therefore, include studies
published after this date. Published congress abstracts or posters
were not included. Abstracts of the retrieved studies were
reviewed independently by both authors for inclusion in the ana-
lysis and any discrepancies resolved by discussion. Of the
retrieved studies, only those pertaining to depression or MDD
were selected. All articles were reviewed. Clinical trials were lim-
ited to randomized controlled trials (RCTs). Open-label, com-
munity-based or naturalistic studies were not included in the
analysis; however, ﬁndings of the analysis are discussed in the
context of the results from these studies and pharmaco-economic
studies. Data were extracted for trial design, participant charac-
teristics and outcomes according to the criteria for RCTs as
detailed in the Consolidated Standards of Reporting Trials
(CONSORT group, 2009) and the Critical Appraisal Skills
Programme (National Health Service, 2009).
Results
The search identiﬁed over 250 citations, of which 21 RCTs
and 18 pooled studies or meta-analyses in MDD were identi-
ﬁed as being suitable for inclusion. The design and outcomes
of the RCTs are summarized in Table 1 (available online).
A summary of the ﬁndings from the published meta-analyses
are shown in Table 2 (available online).
Assessment of escitalopram efficacy
Studies comparing escitalopram with placebo: A large
number of studies have compared escitalopram with placebo,
either with or without an active comparator (i.e. citalopram,
duloxetine or ﬂuoxetine), and their results largely show a ben-
eﬁt of treatment with escitalopram (Bose and Gandhi, 2008;
Burke et al., 2002; Kasper et al., 2005; Lepola et al., 2003;
Nierenberg et al., 2007; Rapaport et al., 2004; Wade et al.,
2002). In ﬁve out of seven studies, escitalopram was signiﬁ-
cantly better than placebo with respect to all measures of
depression (Montgomery-A ˚ sberg depression rating scale
(MADRS), Hamilton rating scale for depression (HAM-D)
and clinical global impression (CGI) scales) (Burke et al.,
2002; Lepola et al., 2003; Nierenberg et al., 2007; Rapaport
et al., 2004; Wade et al., 2002).
Meta-analyses and pooled analyses are important comple-
mentary strategies that can be used to compare diﬀerent ther-
apeutic options (Thase, 2002). The analyses of Wade and
Friis Andersen (2006), Llorca et al. (2005), Lepola et al.
(2004) and Gorman et al. (2002) all showed a statistically
signiﬁcant improvement in MADRS score with escitalopram
compared with placebo after the ﬁrst week of treatment.
In patients who responded after two weeks of treatment,
and continued treatment for the entire eight weeks, 63%
were in remission at the end of the study (Wade and Friis
Andersen, 2006). Similarly, an analysis by Clayton et al.
(2006) revealed that escitalopram was superior to placebo
(and bupropion). A further two analyses explored the
impact of disease severity on the eﬃcacy of escitalopram com-
pared with placebo; ﬁndings were contradictory, with one
analysis reporting a greater diﬀerence between escitalopram
and placebo in patients who were severely depressed at base-
line (Lam and Andersen, 2006), and the other demonstrating
superiority of escitalopram (10mg) over placebo in moder-
ately depressed patients, and superiority of escitalopram
(20mg) over placebo in severely depressed patients (Bech
et al., 2006). More recently, the meta-analysis by Kennedy
et al. (2009) showed a signiﬁcant between treatment eﬀect
of 2.3 MADRS points, representing a signiﬁcant clinical ben-
eﬁt favouring escitalopram versus placebo in MDD.
In the analysis by Svensson and Mansﬁeld (2004),
which reviewed the eﬃcacy of escitalopram compared with
both placebo and citalopram by analysing both published
and unpublished data, the authors challenge the eﬃcacy ﬁnd-
ings with escitalopram, citing potential methodological ﬂaws
in the studies that could account for the diﬀerences between
escitalopram and both placebo and citalopram. It is worth
noting that this early analysis included only a small proportion
of the studies comparing the eﬃcacy of escitalopram with that
of citalopram that have been published to date. Subsequent to
the publication of the analysis by Svensson and Mansﬁeld
(2004), a total of four clinical studies (Colonna et al., 2005;
Lepola et al., 2003; Moore et al., 2005; Yevtushenko et al.,
2007) and ﬁve pooled analyses (Einarson, 2004; Lader et al.,
2005; Lam and Andersen, 2006; Lepola et al., 2004; Llorca
et al., 2005) were published, and these provide further evidence
to support the eﬃcacy ﬁndings reported for escitalopram com-
pared with citalopram.
Studies comparing escitalopram with citalopram: A
total of ﬁve randomized, double-blind studies have directly
compared the eﬃcacy of escitalopram (10–20mg) with that of
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change in MADRS score was signiﬁcantly greater in patients
receiving escitalopram than citalopram at both six
(Yevtushenko et al., 2007) and eight weeks (Burke et al.,
2002; Colonna et al., 2005; Lepola et al., 2003; Moore
et al., 2005). At 24 weeks, however, there was no signiﬁcant
diﬀerence in eﬃcacy between citalopram and escitalopram
(Colonna et al., 2005). In the two placebo-controlled, rando-
mized, double-blind studies in which citalopram was used as
an active comparator, analysis of time to separation from
placebo showed that escitalopram (10–20mg) resulted in a
statistically signiﬁcant separation from placebo on all rating
scales during weeks 1–2, compared with weeks 6–8 for cita-
lopram (20–40mg) (Burke et al., 2002; Lepola et al., 2003).
This suggests that treatment with escitalopram is associated
with earlier relief of depressive symptoms compared with cita-
lopram (Kasper et al., 2006b), which is in keeping with ﬁnd-
ings from preclinical studies (Sanchez, 2006; Sanchez et al.,
2004). Only a single study reported an increased prevalence of
adverse events with citalopram compared with escitalopram
(Yevtushenko et al., 2007); in all other studies, both treat-
ments were found to be equally safe and well tolerated
(Burke et al., 2002; Colonna et al., 2005; Lepola et al.,
2003; Moore et al., 2005).
Furthermore, three pooled analyses have compared the
eﬃcacy of escitalopram with that of citalopram (Gorman
et al., 2002; Lepola et al., 2004; Llorca et al., 2005). In
these three studies, escitalopram was superior to citalopram
with respect to MADRS score (Gorman et al., 2002; Lepola
et al., 2004; Llorca et al., 2005). In the study by Lepola et al.
(2004), for example, the mean decrease from baseline in
MADRS total score in the results of the pooled studies was
greater after eight weeks of treatment in escitalopram-treated
patients than in those treated with citalopram, even in a sub-
population of severely ill patients (i.e. those with MADRS
score of  30). Two early pooled analyses of the initial regis-
tration trials showed a faster onset and superior eﬃcacy of
escitalopram compared with citalopram (Gorman et al.,
2002; Lepola et al., 2004). Data on speed of onset need to
be viewed cautiously because statistical separation is partly
dependent on subject numbers (Taylor et al., 2006b).
Recently, Kennedy et al. (2009) demonstrated a signiﬁ-
cant treatment diﬀerence in terms of MADRS, remission
rates and responder rates favouring escitalopram versus
SSRIs in people with MDD, and the main source of these
diﬀerences were due to diﬀerences between escitalopram
versus citalopram. Similar ﬁndings were obtained in an ana-
lysis of patients with severe depression at baseline.
Positive eﬀects of escitalopram on measures of sleep have
been shown in a study by Lader and colleagues in comparison
with citalopram (Lader et al., 2005). Patients with MDD
associated with sleep problems, deﬁned as MADRS item 4
score  4, were treated with escitalopram, citalopram or pla-
cebo. Patients treated with escitalopram showed improve-
ment in mean MADRS item 4 score at weeks 4, 6 and 8
compared with patients treated with both placebo (p<0.05)
and citalopram (p<0.01). Furthermore, few patients (<6%)
reported sleep-related, treatment-emergent adverse events,
such as daytime somnolence and/or insomnia (Lader et al.,
2005).
Studies comparing escitalopram with other selective
serotonin reuptake inhibitors: The eﬃcacy of escitalo-
pram in MDD has been compared with that of paroxetine
in two randomized, double-blind studies. Escitalopram eli-
cited a statistically signiﬁcant improvement in MADRS,
HAM-D and CGI-severity (CGI-S) scores following 8
weeks of treatment (Boulenger et al., 2006) and, in a sub-
group of severely depressed patients, signiﬁcant improvement
in MADRS score was detected at 27 weeks (Baldwin et al.,
2006). Furthermore, not only was there an increase in the rate
of treatment discontinuations owing to adverse events in par-
oxetine compared with escitalopram-treated patients
(Baldwin et al., 2006; Boulenger et al., 2006), but signiﬁ-
cantly more patients in the paroxetine group withdrew from
the study owing to lack of eﬃcacy (Baldwin et al., 2006).
Only two randomized, double-blind studies compared the
eﬃcacy of escitalopram with that of ﬂuoxetine and these stu-
dies have reported conﬂicting results. The study by Mao et al.
(2008) in Chinese patients showed no signiﬁcant diﬀerence
between the two treatments at 8 weeks, although escitalopram
was superior with respect to both the ‘depressed mood’ and
‘work and interests’ items of the HAM-D scale. The second
study, by Kasper et al. (2005) in elderly patients, suggested
that although ﬂuoxetine was signiﬁcantly less eﬃcacious than
both escitalopram and placebo, escitalopram in turn was not
superior to placebo. The adverse-event proﬁle of the two anti-
depressants was similar (Mao et al., 2008), but there were a
greater number of treatment discontinuations with ﬂuoxetine
compared with escitalopram owing to either adverse events or
lack of eﬃcacy (Kasper et al., 2005).
A single study has explored the comparative eﬃcacy of
escitalopram and sertraline and found no diﬀerences between
agents (Ventura et al., 2007). However, in this study a ﬁxed
dose of escitalopram of 10mg/day, which is the lowest ther-
apeutic dose, was compared with sertraline ﬂexibly dosed
across its entire recommended dose range of 50–200mg/day
(mean dose at week 8: 144mg/day). The similarity in the eﬃ-
cacy of these two antidepressants reported in this clinical
study may not, therefore, translate into clinical practice.
Studies comparing escitalopram with serotonin-
noradrenaline reuptake inhibitors: The eﬃcacy of escita-
lopram has been directly compared with that of venlafaxine
XR in two randomized, double-blind studies, in a total of 484
patients, and found to be very similar (Bielski et al., 2004;
Montgomery et al., 2004), but with some advantage of escita-
lopram in patients with severe MDD (Montgomery et al.,
2006). Three randomized, double-blind studies have compared
the eﬃcacy of escitalopram and duloxetine (Khan et al., 2007;
Nierenberget al.,2007;Pigottet al.,2007;Wadeet al.,2007).
Two of these revealed that patients treated with escitalopram
had greater improvements in MADRS score (Khan et al.,
2007; Wade et al., 2007): one study showed a statistically sig-
niﬁcantly greater eﬃcacy for escitalopram compared with
duloxetine at eight weeks (Khan et al., 2007); the other
demonstrated that the mean change from baseline to week 8
in MADRS score was signiﬁcantly greater in escitalopram-
versus duloxetine-treated patients (Wade et al., 2007).
Another study, designed to establish non-inferiority,
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escitalopram and was associated with similar eﬃcacy over the
8 weeks of the study: 42.6% and 35.2% of patients had a 20%
sustained reduction in HAM-D Maier subscale score with
duloxetine and escitalopram, respectively (p¼0.097). Both
treatments were better than placebo (p<0.001 for duloxetine
versus placebo and p¼0.008 for escitalopram versus placebo)
(Nierenberg et al., 2007). However, in a six-month extension
of this study, there was no signiﬁcant diﬀerence in eﬃcacy
between escitalopram and duloxetine, although escitalopram
did have a signiﬁcantly improved eﬀect on sleep (Pigott et al.,
2007). In a pooled analysis of two clinical studies by Lam and
Wade, the incidence of nausea, insomnia, dizziness and vomit-
ing was statistically signiﬁcantly higher in patients treated with
duloxetine compared with those treated with escitalopram;
however, the incidence of upper respiratory tract infection
was statistically signiﬁcantly higher in patients treated with
escitalopram (Lam et al., 2008). Overall, the authors con-
cluded that escitalopram demonstrated superior tolerability,
as evidenced by lower overall withdrawal rates as a result of
adverse events (Lam et al., 2008). These ﬁndings mirror those
from individual studies comparing escitalopram and duloxe-
tine (Khan et al., 2007; Nierenberg et al., 2007; Pigott et al.,
2007; Wade et al., 2007).
Meta-analysis of studies comparing escitalopram,
selective serotonin reuptake inhibitors and serotonin-
noradrenaline reuptake inhibitors: In addition to the
numerous head-to-head trials of escitalopram and individual
SSRIs and serotonin-norepinephrine reuptake inhibitors
(SNRIs), several meta-analyses were identiﬁed that examined
the relationships between antidepressants in terms of their
eﬃcacy and tolerability. One meta-analysis revealed that esci-
talopram had superior eﬃcacy compared with other antide-
pressants (e.g. citalopram, ﬂuoxetine, paroxetine, sertraline
and venlafaxine XR), as assessed by MADRS on a series of
endpoint comparisons involving change in eﬃcacy scores from
baseline, and response and remission rates (Kennedy et al.,
2006). This meta-analysis included 10 clinical trials and was
designed to detect an overall diﬀerence between escitalopram
and other antidepressants as a group. It did not draw ﬁrm
conclusions on the comparative eﬃcacy of escitalopram and
any one of the individual antidepressants listed, as the number
of studies directly comparing escitalopram with these individ-
ual antidepressants was low. Another meta-analysis byKasper
et al. (2006b) reported similar ﬁndings: the mean change in
MADRS score was found to be signiﬁcantly higher in patients
treated with escitalopram after one week of treatment, and this
beneﬁt persisted for the duration of time that assessments were
made. Interestingly, the CGI-S scores also revealed that esci-
talopram was associated with a faster onset of action than
other antidepressants. An earlier meta-analysis conﬁrmed the
superiority of escitalopram versus citalopram with respect to
both response and remission rates, but found no diﬀerence
between escitalopram and venlafaxine XR (Einarson, 2004).
This is perhaps not surprising given the small number of
patients who received venlafaxine XR in the single study
included in this analysis. Meanwhile, a more recent meta-ana-
lysis by Kennedy et al. (2009), which included 16 studies of
escitalopram of eight weeks’ duration or longer in the treat-
ment of MDD, revealed that escitalopram was associated with
more favourable MADRS scores and remission and responder
rates compared with placebo, SSRIs and SNRIs (Figure 1),
and the results were comparable when the analyses were
restricted to patients with severe depression (baseline
MADRS  30), although the beneﬁt of escitalopram versus
SSRIs was largely due to diﬀerences between escitalopram
versus citalopram.
The recent meta-analysis by Cipriani et al. (2009) con-
cluded that there were clinically important diﬀerences
between antidepressants in terms of eﬃcacy (response rate)
and acceptability (patient discontinuation); the conclusions
were in favour of escitalopram and sertraline. This indepen-
dently funded meta-analysis systematically reviewed 117
RCTs and evaluated 12 commonly prescribed antidepres-
sants, including citalopram, escitalopram, duloxetine, ﬂuoxe-
tine, paroxetine, sertraline and venlafaxine, in 25,928 patients
with unipolar MDD. The methodology used diﬀered from
other meta-analyses, since it incorporated a matrix design
to allow multiple treatment comparisons. The meta-analysis
did not include outcomes such as side-eﬀects, toxic eﬀects,
discontinuation symptoms and social functioning. Mirtaza-
pine, escitalopram, venlafaxine and sertraline were more
Favours comparators
Odds ratio at week 8 (LOCF, all patients)
Odds ratio at week 8 (LOCF, all patients with MADRS  ≥30)
Favours escitalopram
Favours comparators Favours escitalopram
Response odds ratio (95%CI)
Response odds ratio (95%CI)
1.33 (1.15, 1.53)
1.24 (1.06, 1.46)
1.63 (1.23, 2.16)
1.22 (1.06, 1.40)
1.15 (0.98, 1.35)
1.45 (1.10, 1.92)
1.60 (1.33, 1.94)
1.44 (1.15, 1.80)
2.14 (1.48, 3.10)
1.39 (1.06, 1.68)
1.22 (0.98, 1.52)
1.96 (1.36, 2.82)
ESC vs all
ESC vs SSRIs
ESC vs SNRIs
Remission
ESC vs all
ESC vs SSRIs
ESC vs SNRIs
ESC vs all
ESC vs SSRIs
ESC vs SNRIs
Remission
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ESC vs SSRIs
ESC vs SNRIs
0.1
(A)
(B)
11 0
0.1 1 10
Figure 1. Response and remission rates
a following treatment at end
of study (A) for all patients and (B) for severely depressed patients
(permission pending from Kennedy et al., 2009).
aResponse (defined as a  50% reduction in baseline MADRS total score;
LOCF) and remission (defined as MADRS total score  12; LOCF) rates. Data
are odds ratios with 95% CIs.
CI: confidence interval; ESC: escitalopram; LOCF: last observation carried
forward; MADRS: Montgomery-Asberg depression rating scale; SNRI:
selective norepinephrine reuptake inhibitor; SSRI: selective serotonin
reuptake inhibitor.
1146 Journal of Psychopharmacology 24(8)eﬃcacious than duloxetine, ﬂuoxetine, ﬂuvoxamine, paroxe-
tine and reboxetine. Escitalopram, sertraline, citalopram and
bupropion were judged to be more acceptable than the other
antidepressants evaluated. Thus, escitalopram and sertraline
were established as treatments of choice in depression.
Assessment of escitalopram tolerability and safety
In terms of safety and tolerability, data for escitalopram are
available from over 4000 patients in double-blind treatment,
representing approximately 1000 patient-years of exposure
(Baldwin et al., 2007). Overall, the adverse-event proﬁle
detailed in published studies and meta-analyses is consistent
with the known serotonergic properties of escitalopram.
A meta-analysis of safety data from 24 double-blind, active-
comparator or placebo-controlled, randomized studies with
escitalopram was recently published (Baldwin et al., 2007).
The most common adverse events (incidence  5%) reported
during the ﬁrst 8 weeks of treatment with escitalopram, which
were signiﬁcantly more frequent than in the placebo group,
were nausea, insomnia, fatigue, diarrhoea, dizziness, dry
mouth, somnolence and ejaculation failure (Table 3, available
online). The majority of these events were mild to moderate in
severity (Baldwin et al., 2007).
From weeks 8 to 24, only nasopharyngitis (escitalopram
3.2% vs comparator 2.9%) and headache (escitalopram 2.5%
vs comparator 2.6%) had an incidence  2% (Baldwin et al.,
2007). Importantly, particularly for a treatment used long
term in clinical practice, in the heterogeneous patient samples
studied, escitalopram was both safe and well tolerated (Anders
et al., 2008; Kasper et al., 2006a; Wade et al., 2006). No new
types of adverse events were seen in long-term treatment com-
pared with acute treatment (Baldwin et al., 2007; Kasper
et al., 2006a; Wade et al., 2006). Furthermore, weight gain,
which is frequently cited as reason for non-adherence to
long-term SSRI treatment, was not seen after 24 weeks of treat-
ment with escitalopram (Baldwin et al., 2007).
In the same meta-analysis, the safety proﬁle of escitalo-
pram was also compared with other antidepressants, includ-
ing citalopram, ﬂuoxetine, paroxetine, sertraline and
venlafaxine XR. The withdrawal rate at 8 weeks owing to
adverse events was signiﬁcantly lower for escitalopram com-
pared with both paroxetine and venlafaxine XR, and escita-
lopram resulted in fewer discontinuation signs and symptoms
than paroxetine (Baldwin et al., 2007). The latter ﬁnding is
mirrored by a study that utilized telephone calls reporting
symptoms of antidepressant withdrawal received by the
UK national medication helpline between October 1997
and March 2005. Of the total of 1753 calls, 39.4% related
to paroxetine, whereas 0.9% related to escitalopram.
Furthermore, the numbers of calls relating to symptoms of
withdrawal were also high with both venlafaxine XR (14.4%)
and citalopram (8.0%) compared with escitalopram.
However, it is worthwhile noting that the number of calls
relating to symptoms of withdrawal is also dependent on
the number of prescriptions written, and the same study
reported that a much higher number of prescriptions was
dispensed for paroxetine (24.3 million), venlafaxine (12.2 mil-
lion) and citalopram (19.3 million) compared with escitalo-
pram (1.75 million) (Taylor et al., 2006b).
Three randomized, double-blind studies have assessed the
safety of escitalopram compared with that of duloxetine,
which were not included in the analysis by Baldwin et al.
(2007). Duloxetine was associated with an increased incidence
of adverse events, particularly insomnia and constipation
(Nierenberg et al., 2007; Wade et al., 2007), as well as signif-
icant increases in the incidence of nausea, dry mouth, yawn-
ing and vomiting (all p<0.05) (Nierenberg et al., 2007), and
in two out of the three studies, these adverse events accounted
for an increase in the rate of discontinuation in patients trea-
ted with duloxetine compared with those treated with escita-
lopram (Khan et al., 2007; Wade et al., 2007). Although, in
one study, escitalopram was associated with a higher inci-
dence of treatment-emergent sexual dysfunction at 4 weeks
when compared with duloxetine, there was no signiﬁcant dif-
ference at 12 weeks and no diﬀerence in the rates of disconti-
nuations due to sexual dysfunction (Clayton et al., 2007).
Discussion
Clinical benefits of escitalopram compared with other
antidepressants
Over the last ﬁve years, a large body of evidence has accumu-
lated establishing the clinical eﬃcacy and safety of the
S-enantiomer, escitalopram compared with other antidepres-
sants (see summary points below). These ﬁndings provide fur-
ther evidence to support the eﬃcacy ﬁndings reported for
escitalopram compared with citalopram, which had pre-
viously been disputed by Svensson and Mansﬁeld (2004).
It should also be noted that during peer-review of our manu-
script, a post-hoc pooled analysis of data from two 6-month
RCTs was published, which concluded that escitalopram is a
good therapeutic option for the long-term treatment of MDD
(Kasper et al., 2009). In addition, an integrative analysis of
four double-blind, randomized, clinical trials, that was pub-
lished during peer review of our manuscript, concluded that
escitalopram is at least as eﬀective as the SNRIs (venlafaxine
XR and duloxetine), even in severe depression, and was better
tolerated (Kornstein et al., 2009)
Although only a small number of studies have directly com-
pared escitalopram with paroxetine, ﬂuoxetine and sertraline,
these SSRIs have been included in several meta-analyses, which
have evaluated the outcome of multiple clinical trials assessing
the eﬃcacy and tolerability of antidepressants. The most
recent, and perhaps most compelling meta-analysis, by
Cipirani et al. (2009), concluded that escitalopram and sertra-
line might be the best choice of antidepressant when starting
treatment of patients with moderate to severe MDD, since they
oﬀer the best ratio of eﬃcacy and acceptability. It is notewor-
thy that escitalopram and citalopram were compared sepa-
rately in this meta-analysis (Cipriani et al., 2009).
A number of meta-analyses suggest that the SNRI venla-
faxine XR is associated with greater remission or response
rates in patients with MDD compared with SSRIs (Nemeroﬀ
et al.,2008;Papakostaset al.,2007;Smithet al.,2002;Thase,
2008; Thase et al., 2005). These results have prompted some
authors to debate whether dual-action antidepressant drugs
that combine both a serotonergic and noradrenergic mecha-
nism of action are more eﬀective in patients with MDD than
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eﬃcacy of escitalopram in comparison with the SNRIs venla-
faxine XR and duloxetine may have been limited by the small
number of studies directly comparing these agents; however,
these studies were performed in a large number of patients
(>1500 patients) and, thus, were suﬃciently powered to iden-
tify important clinical diﬀerences between the treatments
(Cipriani et al., 2009).
Summary points for eﬃcacy:
(i) eﬃcacy advantage for escitalopram versus citalopram
has been demonstrated in ﬁve randomized studies
(Burke et al., 2002; Colonna et al., 2005; Lepola et al.,
2003; Moore et al., 2005; Yevtushenko et al., 2007) and
two pooled analyses of clinical trials (Gorman et al.,
2002; Lepola et al., 2004);
(ii) escitalopram may have an eﬃcacy advantage over par-
oxetine, in terms of signiﬁcant improvements in
MADRS, HAM-D and CGI-S scores and fewer discon-
tinuations owing to lack of eﬃcacy (Baldwin et al.,
2006; Boulenger et al., 2006);
(iii) the eﬃcacy of escitalopram compared with ﬂuoxetine
(Mao et al., 2008; Kasper et al., 2005) and sertraline
(Ventura et al., 2007) requires further evaluation;
(iv) escitalopram and sertraline might be the best choice of
antidepressant when starting treatment of patients with
moderate to severe MDD (Cipriani et al., 2009);
(v) the SNRI venlafaxine XR may be associated with
greater remission or response rates in patients with
MDD compared with SSRIs (Papakostas et al., 2007;
Smith et al., 2002; Nemeroﬀ et al., 2008; Thase, 2008
Thase et al., 2005; Burk et al., 2002);
(vi) escitalopram has comparable eﬃcacy to venlafaxine XR,
with a possible slight advantage for escitalopram in
patients with severe MDD (Bielski et al., 2004;
Montgomery et al., 2004)
Regarding safety and tolerability, escitalopram oﬀers toler-
ability advantages over duloxetine, paroxetine and venlafaxine
XR (see summary points below) and may be preferable to
those antidepressants in some patients with MDD.
Summary points for safety:
(i) superior tolerability for escitalopram versus duloxetine,
particularly for nausea, insomnia, dizziness and vomit-
ing has been demonstrated in three randomized studies
(Khan et al., 2007; Nierenberg et al., 2009; Wade et al.,
2007) and a pooled analysis of two clinical trials (Lam
et al., 2008)
(ii) escitalopram oﬀers tolerability advantages over paroxe-
tine (Baldwin et al., 2006; Boulenger et al., 2006) and
venlafaxine XR (Bielski et al., 2004; Montgomery et al.,
2004, 2006);
(iii) escitalopram is less likely to cause discontinuation symp-
toms than several other antidepressants (Baldwin et al.,
2006; Bielski et al., 2004; Boulenger et al., 2006; Kasper
et al., 2005; Khan et al., 2007; Montgomery et al.,
2004, 2006; Taylor et al., 2006a; Wade et al., 2007);
(iv) no evidence of emergent risk of suicide with escitalopram
(Baldwin et al., 2007; Pedersen, 2005);
(v) incidence of sexual dysfunction-related adverse events
similar to citalopram, but lower than venlafaxine XR
and paroxetine (Baldwin et al., 2007).
Why might escitalopram confer clinical advantages to
citalopram?
Careful consideration of a drug’s stereochemistry is becoming
increasingly important when developing new antidepressants
to provide greater insight into the pharmacological subtleties
of the agents being prescribed in clinical practice (Baumann
et al., 2002). It can be postulated that the observed clinical
beneﬁts of escitalopram compared with citalopram are con-
ferred by the pharmacological and pharmacodynamic proper-
ties of the constituent enantiomers. These properties are
summarized below.
In addition to overall clinical eﬃcacy in terms of symptom
improvement, another potential clinical advantage that esci-
talopram may confer compared with citalopram is earlier
onset of action (Kasper et al., 2006b). Increasing attention
has been focused on the requirement for antidepressant med-
ications to have a rapid onset of eﬀect (Blier, 2003;
Rosenbaum, 2001; Taylor et al., 2006b), since this can trans-
late into clinical beneﬁt in terms of symptom control and
treatment continuation (Kasper et al., 2006b). Initial clinical
results (Kasper et al., 2006b), which were identiﬁed in the
literature search (Table 1, available online), suggested that
escitalopram had a faster onset of action compared with cita-
lopram (see summary points below). It has been suggested
that the reduction in serotonergic activity as a result of auto-
receptor activation is the rate-limiting step in the clinical
response to antidepressants. Therefore, more rapid desensiti-
zation of the receptors, as observed with escitalopram, could
lead to a faster onset of action (El Mansari et al., 2005).
Summary points for escitalopram versus citalopram:
(i) escitalopram (S-enantiomer) has improved pharmaco-
logical potency as a serotonin reuptake inhibitor in
vitro versus the R-enantiomer; the S-enantiomer has
the beneﬁt of allosterically modulating the SERT;
(Hyttel et al., 1992)
(ii) the R-enantiomer is metabolized more slowly than the
S-enantiomer (Sidhu et al., 1997), resulting in approxi-
mately two-fold higher plasma concentration of the
R-enantiomer (Overo, 1982; Tanum et al., 2003);
(iii) R-citalopram may have a functional antagonistic eﬀect on
escitalopram (Cremers and Westerink, 2003; El Mansari
et al., 2005; Lucki and Brown, 2003; Mørk et al., 2003;)
withsigniﬁcantlyhigheroccupancy6hpost-dosewithesci-
talopram (10mg/day: 82%) compared with citalopram
(20mg/day: 64%) (Klein et al., 2007; Meyer et al., 2004);
(iv) R-citalopram should not be considered an inactive enan-
tiomer: it may have a deleterious inﬂuence on the activity
of escitalopram through functional antagonism
(El Mansari et al., 2007);
(v) escitalopram may have a faster onset of action than cita-
lopram (Sanchez, 2003; Sanchez et al., 2003a, b) as a result
of more rapid desensitization of 5-hydroxytryptamine1A
subtype autoreceptors, leading to more rapid disinhibition
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otonin (Blier and Bouchard, 1994).
Translating clinical efficacy into ‘real-life’ benefit
The outcomes of naturalistic studies can provide insight into
the use of escitalopram in the wide range of patients with
MDD seen in clinical practice. While evidence-based medicine
is the main platform upon which treatment eﬃcacy is evalu-
ated, it is important that the ﬁndings from RCTs translate
into real, everyday clinical practice. The patient populations
of RCTs are typically homogeneous as they are determined
based on the stringent inclusion and exclusion criteria
required for regulatory approval of a speciﬁc indication;
therefore, for a treatment to be clinically relevant, the results
from RCTs must apply to the broader population of patients
treated in psychiatric and primary care practices. However,
although studies conducted under ‘real-life’ conditions pro-
vide valuable insight into the eﬃcacy of the drug in a popu-
lation that is representative of outpatients suﬀering from
depression, the ﬁndings from such studies cannot be included
in meta-analyses that determine the overall treatment eﬀect.
A number of such naturalistic studies have been conducted
with escitalopram and their ﬁndings are consistent with those
reported in RCTs (Lancon et al., 2006; Moller et al., 2007;
Rush and Bose, 2005). In these studies, 8 weeks of treatment
with escitalopram was associated with improvements in mea-
sures of depression, including MADRS score and CGI-
improvement score (Moller et al., 2007; Rush and Bose,
2005). These ﬁndings were corroborated by a large-scale,
uncontrolled open-label study of Moller et al., in which
over 11,500 patients were treated and 83% showed much or
very much improved CGI-I (Moller et al., 2007).
The long-term eﬃcacy of escitalopram, in terms of
improved symptom severity, has been demonstrated in a
number of six- or 12-month open-label studies (Anders
et al., 2008; Kasper et al., 2006a; Wade et al., 2006), in
which the majority of patients (72% to 86%) achieved remis-
sion (MADRS  12). It would, therefore, appear that the
mechanistic advantages of escitalopram over citalopram, in
terms of increased potency (Hyttel et al., 1992) and its known
eﬀect on the SERT through an aﬃnity-modulating allosteric
site (Chen et al., 2005), translate into clinical beneﬁts in
patients with MDD, as demonstrated in the pooled analysis
by Llorca et al. (2005), which showed signiﬁcantly greater
mean change from baseline in MADRS with escitalopram
versus citalopram (56% vs 41%, respectively; p¼0.007).
In addition to the requirement for eﬃcacy and safety, it is
pertinent that an antidepressant agent is cost-eﬀective. In
2007, the cost of treating depression, including both direct
and indirect costs, was estimated at 118 billion per year in
Europe (Lam and Annemans, 2007). Several pharmaco-eco-
nomic studies have suggested that escitalopram may be more
cost-eﬀective than citalopram (Croom and Plosker, 2003;
Demyttenaere et al., 2005; Fantino et al., 2007; Franc ¸ ois
et al., 2003; Hemels et al., 2004; Sorensen et al., 2007;
Wade et al., 2005a, b; Wu et al., 2008) and duloxetine
(Wade et al., 2008) and at least as cost-eﬀective as venlafax-
ine XR (Croom and Plosker, 2004; Demyttenaere et al., 2005;
Fernandez et al., 2005; Kulp et al., 2005; Llorca and
Fernandez, 2007; Sorensen et al., 2007). These results suggest
that the improved eﬃcacy of escitalopram, both in clinical
trials and in ‘real life’, translate into improved cost-eﬀective-
ness, thereby relieving some of the burden of depression on
healthcare authorities and this is supported by Cipriani et al
(Cipriani et al., 2009). However, it should be noted that the
cost-eﬀective analyses were conducted when venlafaxine XR
was under patent and this should be considered when inter-
preting these data.
Limitations of this literature review
It is important to acknowledge a number of potential limita-
tions of this literature review article, which are common to all
review articles of this nature. These include publication bias,
i.e. the selective publication of trials with positive results, and
diﬀerences in study design, including dosing regimens, sample
sizes and inclusion criteria (Davis et al., 1995; Davey Smith
and Egger, 1998; Egger and Smith, 1998).
An important consideration when interpreting these ﬁnd-
ings is the issue of dose comparability. Ideally, individual stu-
dies included in any review, qualitative or quantitative, should
involve dosing across the full regulatory-approved dose range
for each treatment group. If this is not the case, in order to
ensure fair comparability between the two treatment groups,
the study should assess the eﬃcacy of minimal doses of drug A
with minimal doses of drug B, and high doses should be com-
pared with high doses (Lieberman et al., 2005). The dose of
escitalopram used across the studies included in this review
ranged from 10 to 20mg, which is the dose range approved
in Europe. All of the included studies comparing escitalopram
and citalopram involved comparable doses. However, it should
be pointed out that the majority of these comparative studies
used ﬁxed doses of escitalopram and citalopram and it is pos-
sible that these ﬁxed-dose studies simply used more eﬀective
doses of escitalopram than citalopram. Some of the compara-
tive studies with other antidepressants cannot be considered to
be dose comparable and this should, therefore, be considered
when interpreting their ﬁndings; for example, in the study by
Montgomery and colleagues, 10–20mg of escitalopram was
compared with 75–150mg of venlafaxine XR (Montgomery
et al., 2004).
In addition, many of the studies included here involved
relatively small samples of patients, which may limit interpre-
tation owing to insuﬃcient power to detect reliably the diﬀer-
ences between two eﬀective treatments (Thase, 1999, 2002).
However, the combining of data in meta-analyses helps to
overcome this potential limitation.
Finally, although changes in scores on clinical scales such as
the MADRS and HAM-D, are well-established measures of clin-
ical eﬃcacy, antidepressants can also be assessed using validated
surrogate outcomes, which may be better measures of ‘real-life’
eﬃcacy, such as remission rates, quality of life, patient-reported
outcomes and productivity (Lam and Annemans, 2007); for
example, the recent study by Demyttenaere et al. (2008),
showed that patients treated with escitalopram reported a sta-
tistically and clinically signiﬁcant improvement in quality of life
enjoyment and satisfaction using data from eight randomized,
eight-week, clinical trials. This review did not assess eﬃcacy in
terms of these patient-centred outcomes; however, a number of
Leonard and Taylor 1149observational or naturalistic studies were included, and these can
be assumed to better capture treatment eﬃcacy in the ‘real-life’
clinical setting.
Conclusions
In the recent past it has been thought that there is very little
diﬀerence in both eﬃcacy and safety between antidepressants
currently available. However, there is evidence suggesting
that the mechanistic advantages of escitalopram over the R-
enantiomer and racemic citalopram translate into clinical eﬃ-
cacy beneﬁts, both in the context of clinical studies and the
‘real-life’ setting. In addition, there is evidence that the onset
of treatment response is earlier with the S-enantiomer alone.
Evidence for an eﬃcacy advantage over other SSRIs and
SNRIs is less robust, but escitalopram does appear to oﬀer
some tolerability advantages over several other antidepres-
sants, particularly the SNRIs, venlafaxine XR and duloxe-
tine. Escitalopram is, therefore, associated with a favourable
beneﬁt-risk ratio compared with some other antidepressant
agents. These advantages, seem to be associated with the
drug’s unique chemistry and pharmacological actions.
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